The third vaccine in the running, Bharat Biotech’s Covaxin, being developed in collaboration with the Indian Council of Medical Research (ICMR), is simultaneously undergoing Phase 3 human trials across 22 sites in India with around 26,000 volunteers.
According to a top official from the company, it will be at least 60 percent effective based on earlier trial results.
Vaccine Roll-Out, Dry Run
On 31 December, the Centre had asked all states and Union territories to gear up for the COVID-19 vaccine roll-out and a dry-run would be conducted countrywide on 2 January.
The objectives of the dry run would be to “assess operational feasibility in the use of Co-WIN application in field environment, test the linkages between planning and implementation and identify the challenges and guide way forward prior to actual implementation,” a press release by the government stated.
The activity will also focus on difficult terrains and regions with poor logistical support.
The dry run in the states…